Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (901)	4/21/2000 10:25:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 52153

Catching up, RE: FRX, kinda surprised at seing FA like this in this sector. wsrn.com biz.yahoo.com Forest Laboratories Announces Agreement with Merckle GmbH for Osteoarthritis Drug <<Howard Solomon, Chairman and Chief Executive Officer of Forest, said: ``Our agreement with Merckle reflects our business strategy of partnering with companies that have promising compounds with very high market potential. New treatments to manage osteoarthritis are needed because there are many patients who are not adequately treated with the medications currently available. In addition, recent data indicates that the selective COX-2 inhibitors, although reducing serious gastrointestinal events, may fail to reduce thromboembolic events as do inhibitors of COX-1. This is because COX-1 promotes platelet aggregation so that inhibiting COX-1 tends to inhibit thromboembolic events such as myocardial infarction or stroke. Therefore ML3000, a combined inhibitor of COX-1 and COX-2 and LO, in addition to being effective in the treatment of osteoarthritis, may also reduce incidence of serious gastrointestinal events caused by the traditional NSAID's, while retaining the ability to reduce thromboembolic events due to its COX-1 inhibition. We believe therefore that a novel compound like ML3000 could obtain a significant share of the $5 billion anti-arthritic market.>> sounds like it has potential. I was on Naprosyn for 3 weeks for accute tendonitis, and after 3 weks, I literally could not stomach it anymore. When I was put back on NSAIDs for my spine, I had to take Relafen (less GI effects) PLUS take cytotec to rebuild the mucosal lining the NSAIDS were trashing. Scott